PK/PD Properties and Safety of Remazolam Besylate for Injection in ICU Patients With Impaired Renal Function

PHASE2RecruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

November 4, 2023

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Mechanically Ventilated Patients
Interventions
DRUG

Remimazolam besylate

After a loading dose of 0.05mg/kg, a maintaining dose of 0.2mg/kg/h is given; It is recommended to adjust the infusion rate of Remazolam besylate for injection at a amplitude of 0.05mg/kg/h, mainly based on the RASS score of the subjects (the adjustment range is 0-1.0 mg/kg/h, and the maximum infusion rate is not more than 1.0mg/kg/h) until the subjects reach the optimal sedation level (-3≤RASS≤0).

Trial Locations (1)

430022

RECRUITING

Wuhan Union Hospital, Wuhan

All Listed Sponsors
collaborator

Yichang Humanwell Pharmaceutical Co., Ltd., China

INDUSTRY

lead

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

OTHER